Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation

1991 ◽  
Vol 36 (12) ◽  
pp. 1735-1740 ◽  
Author(s):  
S. Bondesen ◽  
J. Hegnh�j ◽  
F. Larsen ◽  
S. Honor� Hansen ◽  
C. P. Hansen ◽  
...  
Keyword(s):  
Slow Release ◽  
Intravenous Bolus ◽  
Aminosalicylic Acid ◽  
Release Formulation ◽  
Slow Release Formulation

scholarly journals Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 886-888 ◽  
Author(s):  
P Deltenre ◽  
A Berson ◽  
P Marcellin ◽  
C Degott ◽  
M Biour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Adverse Effects ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Safe Alternative ◽  
Release Formulation ◽  
Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis

1992 ◽  
Vol 30 (13) ◽  
pp. 50-52
Keyword(s):  
Ulcerative Colitis ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Release Formulation ◽  
Delayed Release ◽  
Slow Release Formulation ◽  
Chemical Combination ◽  
Pharmacokinetic Properties ◽  
Enteric Coated

Four drugs based on 5-aminosalicylic acid (5-ASA) are now available for the treatment of ulcerative colitis. Salazopyrin (sulphasalazine) is a chemical combination of 5-ASA plus sulphapyridine, and Dipentum (olsalazine) a chemical combination of two molecules of 5-ASA. Asacol (mesalazine e.c.) is 5-ASA alone but in an enteric-coated, delayed-release formulation and Pentasa (mesalazine s.r.) 5-ASA in a slow-release formulation. In this article we look at the pharmacokinetic properties of these alternatives and discuss how they influence choice.

Pharmacokinetics of a Slow-Release Formulation of Soybean Isoflavones in Healthy Postmenopausal Women

2005 ◽  
Vol 53 (6) ◽  
pp. 1938-1944 ◽  
Author(s):  
Kenneth D. R. Setchell ◽  
Amnon Brzezinski ◽  
Nadine M. Brown ◽  
Pankaj B. Desai ◽  
Murad Melhem ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Slow Release ◽  
Release Formulation ◽  
Soybean Isoflavones ◽  
Slow Release Formulation

Depronal SA: sustained-action dextropropoxyphene

1972 ◽  
Vol 10 (10) ◽  
pp. 40-40
Keyword(s):  
Analgesic Effect ◽  
Slow Release ◽  
Narcotic Drug ◽  
Release Formulation ◽  
Slow Release Formulation ◽  
Sustained Action

Depronal SA is a slow-release formulation of dextropropoxyphene,1 a synthetic non-narcotic drug with about the same analgesic effect as codeine. The drug is available alone as 65 mg capsules (Doloxene) and also mixed with various other drugs, e.g. as Doloxene Co-65 (with aspirin, phenacetin and caffeine) and as Distalgesic (with paracetamol).

scholarly journals IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation

2014 ◽  
Vol 192 (12) ◽  
pp. 5813-5820 ◽  
Author(s):  
Esther D. Quakkelaar ◽  
Marieke F. Fransen ◽  
Wendy W. C. van Maren ◽  
Joost Vaneman ◽  
Nikki M. Loof ◽  
...  
Keyword(s):  
B Cell ◽  
Slow Release ◽  
Peptide Vaccine ◽  
Cell Epitope ◽  
Release Formulation ◽  
Slow Release Formulation ◽  
B Cell Epitope
Sign in / Sign up

Export Citation Format

Share Document